Menu Search
Equities

Syros Pharmaceuticals Inc

0LC7:LSE

Syros Pharmaceuticals Inc

Actions
  • Price (USD)0.3564
  • Today's Change-2.51 / -87.55%
  • Shares traded3.24m
  • 1 Year change-88.47%
  • Beta--
Data delayed at least 20 minutes, as of Nov 13 2024 19:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Syros Pharmaceuticals Inc's revenues fell -33.23% from 14.88m to 9.94m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 94.65m to a larger loss of 164.57m.
Gross margin--
Net profit margin-25,340.67%
Operating margin-28,927.20%
Return on assets-84.04%
Return on equity-776.96%
Return on investment-111.15%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Syros Pharmaceuticals Inc fell by 28.91m. Cash Flow from Financing totalled 43.46m or 437.42% of revenues. In addition the company used 109.71m for operations while cash from investing totalled 37.34m.
Cash flow per share-2.62
Price/Cash flow per share--
Book value per share-0.4145
Tangible book value per share-0.4145
More ▼

Balance sheet in USDView more

Syros Pharmaceuticals Inc has a Debt to Total Capital ratio of 137.13%, a higher figure than the previous year's 108.55%.
Current ratio2.25
Quick ratio--
Total debt/total equity--
Total debt/total capital1.37
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.